Generation of bivalent chromatin domains during cell fate decisions. by De Gobbi, M. et al.
RESEARCH Open Access
Generation of bivalent chromatin domains
during cell fate decisions
Marco De Gobbi1, David Garrick1, Magnus Lynch1, Douglas Vernimmen1, Jim R Hughes1, Nicolas Goardon1,
Sidinh Luc2, Karen M Lower1, Jacqueline A Sloane-Stanley1, Cristina Pina1, Shamit Soneji1, Raffaele Renella1,
Tariq Enver1, Stephen Taylor3, Sten Eirik W Jacobsen2, Paresh Vyas1,4, Richard J Gibbons1 and Douglas R Higgs1*
Abstract
Background: In self-renewing, pluripotent cells, bivalent chromatin modification is thought to silence (H3K27me3)
lineage control genes while ‘poising’ (H3K4me3) them for subsequent activation during differentiation, implying an
important role for epigenetic modification in directing cell fate decisions. However, rather than representing an
equivalently balanced epigenetic mark, the patterns and levels of histone modifications at bivalent genes can vary
widely and the criteria for identifying this chromatin signature are poorly defined.
Results: Here, we initially show how chromatin status alters during lineage commitment and differentiation at a
single well characterised bivalent locus. In addition we have determined how chromatin modifications at this locus
change with gene expression in both ensemble and single cell analyses. We also show, on a global scale, how
mRNA expression may be reflected in the ratio of H3K4me3/H3K27me3.
Conclusions: While truly ‘poised’ bivalently modified genes may exist, the original hypothesis that all bivalent
genes are epigenetically premarked for subsequent expression might be oversimplistic. In fact, from the data
presented in the present work, it is equally possible that many genes that appear to be bivalent in pluripotent and
multipotent cells may simply be stochastically expressed at low levels in the process of multilineage priming.
Although both situations could be considered to be forms of ‘poising’, the underlying mechanisms and the
associated implications are clearly different.
Background
In recent years it has been suggested that the epigenetic
programme may play a key role in determining cell fate,
including the decision to undergo self-renewal or com-
mitment. Based on genome-wide chromatin immuno-
precipitation (ChIP) studies combined with expression
analysis, it has been suggested that the chromatin asso-
ciated with many genes controlling lineage fate decisions
is uniquely marked in stem cells. Their histone signature
is referred to as bivalent as it includes modifications
associated both with repression (H3K27me3) imposed
by the polycomb group proteins (PcG), and activation
(H3K4me3) encoded by the Set/MLL histone methyl-
transferase, the mammalian homologue of the trithorax
group proteins (trxG) [1-6]. Despite having both ‘active’
and ‘repressive’ chromatin marks, such genes were
thought not to be expressed. Taken together, these
observations led to an attractive model suggesting that a
preimposed epigenetic signature suppresses expression
of lineage control genes in stem cells (maintaining a
pluripotent state) while at the same time ‘poising’ such
genes for subsequent activation (reviewed in [7]). In
favour of this, many lineage-control genes have a biva-
lent signature [1-5]. However, as the model has evolved,
more recently it has been shown that RNA polymerase
II (PolII) may be present but stalled at the promoters of
bivalent genes [8,9] and that short (abortive) transcripts
may be detected at their promoters [10]. Furthermore,
although embryonic stem cells (ES cells) lacking the
PcG repressive complex 2 (PRC2) aberrantly express
developmental regulators [11] they maintain pluripo-
tency [12]. Similarly, two recent experiments in which
components of the SET1/MLL core subunit (Dpy-30,
RbBP5 and WDR5) were reduced to similar levels
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showed opposite phenotypes. In one study there was
maintenance of self-renewal with a defect in differentia-
tion [13], and in another there was a loss of self-renewal
[14]. Together these observations suggest that the cur-
rent models explaining the significance bivalently
marked chromatin may require revision.
An understated problem in testing the prevailing biva-
lent chromatin hypothesis is that the criteria for identi-
fying such signatures are poorly defined. Closer analysis
of publicly available chromatin datasets from human
embryonic stem (ES) cells shows that even contiguous
bivalent chromatin domains can be modified in widely
different ways with respect to the relative levels and the
distributions of H3K4me3 and H3K27me3 across the
locus (see Additional file 1). Sequential ChIP analyses of
a few developmental genes have shown that H3K4me3
and H3K27me3 may colocalise and, by extrapolation, it
has been implied that all genes whose promoters are
marked (to any degree) by both modifications are truly
bivalent. According to this paradigm, many specialised,
lineage-specific genes are bivalent [3,4,15] and as cells
differentiate, chromatin modifications resolve into active
or repressed states. However, since the original observa-
tions, it has become clear that bivalent chromatin modi-
fications (indistinguishable from those seen in
pluripotent cells) can also be newly established and/or
maintained in differentiating cells [16-19]. Therefore,
the functional significance of such bivalently marked
genes has been questioned [20] and more studies have
been urged to determine the mechanisms underlying
these chromatin structures [19].
The human a globin genes are located within a well
characterised multigene cluster whose analysis has eluci-
dated many of the general principles underlying the
transcriptional and epigenetic regulation of mammalian
gene expression. The a globin cluster (5’-HBZ-HBM-
HBA2-HBA1-HBQ-3’) provides unequivocal examples of
specialised, tissue-specific genes consistently scored as
bivalent in ES cells [4,5] (Figure 1). Their fully activated
expression depends on one or more of four remote con-
served regulatory elements (MCS-R1 to R4) [21], which
interact with their promoters in erythroid cells via a
looping mechanism [22]. Although expressed in a
strictly tissue-specific and developmental-stage-specific
manner during erythropoiesis, the a globin promoters
and much of the body of the associated genes lie within
unmethylated CpG islands [23]. Previously, we have
described many aspects of the transcription factor and
epigenetic programmes associated with hematopoiesis
and how they are played out on the a globin cluster
[24-27]. Here, we have used this model to investigate in
detail the relationship between chromatin marks and
mRNA expression during commitment and differentia-
tion into erythroid cells. It appears that, rather than
carrying a preimposed bivalent epigenetic signature
which silences them, in pluripotent ES cells the a globin
genes are repressed by PcG and comodified at readily
detectable levels by H3K4me3 when expressed, even at
basal levels. To ensure that characterisation of the a
globin genes is revealing a general principle that could
be relevant to other bivalent genes, we performed global
analysis of H3K4me3/H3K27me3 modification and gene
expression. The results suggest that our understanding
of chromatin bivalency at the a globin locus may
explain similar marks found at many other bivalent
genes both in pluripotent and differentiating cells and
highlights an alternative mechanism for generating biva-
lent domains.
Results and discussion
H3K4me3 at the a globin genes occurs at a low but
significant level in ES cells and increases during erythroid
differentiation
To dissect the mechanism(s) underlying epigenetic ‘biva-
lency’ in ES cells, we studied histone modifications
across the telomeric region of chromosome 16 contain-
ing the human a globin locus. We found that, whereas
H3K4me1 and H3K4me2 were both enriched at the a
globin locus (Figure 1a, i and 1ii), H3K4me3 (considered
to be a sensitive mark of recent or ongoing transcrip-
tional activity) was relatively low (Figure 1a, iii). How-
ever, quantitative real time PCR (qPCR) (Figure 1b, iii)
showed that the level of H3K4me3 at the a globin pro-
moter in ES cells was significantly higher than in lym-
phocytes in which the a globin genes are considered to
be fully repressed (see below). Similar results were
obtained at the promoter of the HBM gene, a minor a
globin-like gene whose promoter is also associated with
a large CpG island [28].
To quantify this low level of H3K4me3, we compared
the degree of enrichment seen in pluripotent ES cells to
that seen in an artificially mixed population of erythroid
and non-erythroid cells. This showed (Figure 1b, iii) that
the H3K4me3 enrichment seen in ES cells at the a globin
gene was even less than that obtained in a mixed popula-
tion of cells consisting of 10% erythroid cells (presumably
fully modified by H3K4me3) (Figure 1b, iii) and 90% lym-
phocytes (unmodified by H3K4me3, Figure 1b, iii).
These results show that the chromatin associated with
the a globin genes is modified at a significant but low
level by H3K4me3 in chromatin derived from a popula-
tion of pluripotent stem cells. However, the level of
H3K4me3 modification increases dramatically (15-fold)
as cells differentiate into erythroid cells (Figure 1b, iii).
This phenomenon is common to many other genes
(previously noted to be bivalent in ES cells), which are
expressed at high levels late in erythroid differentiation
(for example, BLVRB, FAM83F, MTSS1, TNXB) [18].
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Conversely, H3K4me3 is barely detectable in lympho-
cytes in which the a globin genes are repressed.
H3K27me3 at the a globin genes occurs at high levels in
ES cells and decreases during erythroid differentiation
We have previously shown that a globin expression is
repressed in non-erythroid cells by PcG and its asso-
ciated silencing mark H3K27me3. This repression is put
in place early in development and then is either reduced
in the erythroid lineage or maintained in non-globin-
expressing cell types [27].
Here, we extended these observations to determine
the pattern of H3K27me3 in pluripotent cells across the
telomeric 500 kb of chromosome 16p. As noted in sev-
eral non-erythroid differentiated cells [27], H3K27me3
enrichment extended across a broad region of the a glo-
bin cluster in ES cells (Figure 1a, iv).
Of importance, we next determined the relative levels
of H3K27me3 enrichment at the HBM and a globin
promoters in ES cells and lymphocytes in which the a
globin genes are repressed. ChIP-chip results (Figure 1,
iv and [27]), in accordance with qPCR data (Figure 1b,
iv), indicate that the locus is modified to a similar extent
in both cell types. These findings suggest that the a glo-
bin genes are highly (possibly maximally) modified by
H3K27me3 in pluripotent cells and that this level of
modification is maintained when cells differentiate into
non-erythroid lineages. By contrast, in the erythroid
population, as the PcG is completely cleared [27],
H3K27me3 is reduced fourfold compared to that seen in
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Figure 1 Chromatin marks at the telomeric region of chromosome 16p in embryonic stem (ES) cells. (a) The genes, multispecies
conserved regulatory sequences (MCS-R1-4) and CpG islands (CGI) are shown at the top. The red shaded box represents the a globin cluster.
The y axis represents the enrichment of chromatin immunoprecipitation (ChIP) DNA over input DNA. (b) ChIP quantitative PCR (qPCR) data at
selected amplicons. Ery = primary human erythroblasts; Ery10% = mixed population consisting of 10% erythroblasts and 90% Ly; ES = human ES
cells; Ly = Epstein-Barr virus (EBV)-transformed lymphoblastoid cell line. The fold enrichment has been calculated relative to a control sequence
in the ACTB promoter. The error bars show the standard deviation of three independent experiments. **P < 0.05; ***P < 0.01 (both by Student’s
t test).
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non-erythroid cells (Figure 1b, iv) but not totally
removed.
The a globin locus is bivalently modified in ES cells
Chromatin modification at the a globin locus thus
resembles that seen at other bivalent domains (for
example, CDX2 (see Additional file 1)) at which there is
a high level of H3K27me3, and a low level of H3K4me3
which increases (with expression) or decreases (with
silencing) in specific lineages as cells differentiate. To
determine if the observed bivalent architecture results
from colocalisation of H3K27me3 and H3K4me3 rather
than simply reflecting the presence of two distinct sub-
populations of active and silent cells, we performed
sequential ChIP analyses.
At a globin and HBM promoters, chromatin precipi-
tated with an antibody against H3K27me3 was sequen-
tially precipitated by an antibody against H3K4me3
(Figure 2a). Similar results were seen by the ‘reverse’
sequential ChIP (Figure 2b). This shows that at least
some chromatin at the a globin genes is truly comodi-
fied by H3K27me3 and H3K4me3.
The a globin locus is expressed at basal levels in a
significant proportion of pluripotent cells
Chromatin modification may influence the probability
that a locus is transcribed and/or reflect its recent tran-
scriptional state. As for many bivalent genes, the asser-
tion that the a globin genes are not expressed in
pluripotent cells is based on the failure to identify bind-
ing of PolII in ChIP experiments and the very low
(background) signals obtained on RNA microarray ana-
lyses. However, using more sensitive assays it has
become increasingly clear that in pluripotent cells many
bivalent genes are being transcribed either to produce a
variety of short, abortive transcripts [8,10] or to produce
very low levels of full length RNA transcripts [15,29].
To determine the transcriptional status of the a globin
bivalent domain, we firstly looked for, but could not
detect, high levels of 5’ abortive transcripts (see Addi-
tional file 2). Then, we analysed expression of spliced
transcripts at the cell population level. We found that in
ES cells the level of a globin mRNA, although very low
compared to erythroblasts (approximately 30,000 to
40,000 times less), was at least 10 times higher than that
measured in Epstein-Barr virus (EBV)-transformed lym-
phoblastoid (EBV-Ly) cell lines (Figure 3a). Similarly,
HBM mRNA could be detected in ES cells (although 50
times less than a globin) but was not detectable in lym-
phoblastoid cells (see Additional file 2). The lower
expression of HBM than a globin might be due to differ-
ences in promoter sequences or in mRNA stability of this
minor globin gene [28]. By comparison, no b globin RNA
transcripts were detected in ES and lymphoblastoid cells.
We next estimated how many ES cells within each popu-
lation express a globin using single-cell RT-PCR with
primers that detect full-length mRNA transcripts. Using
a multiplex analysis, this showed a detectable level of a
globin in 12% of OCT4 positive ES cells (Figure 3b).
Since a single normal erythroid cell contains approxi-
mately 20,000 (a + b) globin RNA molecules [30], it can
be estimated that pluripotent ES cells express a globin
only at basal (two or three copies per cell) levels. This is
consistent with observations that chromatin modifica-
tions (H3K36me3 and H3K9me3) associated with high
rates of transcription were not detected in ES cells (see
Additional file 3). By contrast, no a globin expression
was detected in more than 100 EBV-Ly cells (Figure 3c),
confirming that in these cells, unlike ES cells, the state of
chromatin at the a globin locus is in a completely
repressed transcriptional configuration.
Changes in expression and chromatin modification in
hematopoietic stem cells and progenitors
To examine how a globin expression changes during
hematopoiesis, we studied primary hematopoietic pro-
genitors at various stages of commitment and differen-
tiation (Figure 3a). Mixed populations enriched for
hemopoietic stem cells (HSCs) and common myeloid
progenitors (CMPs) exhibited a level of a globin gene
expression higher than in ES cells. Expression then
increased further in fractions enriched for megakaryo-
cyte-erythroid progenitors (MEPs) but decreased in
granulocyte-monocyte progenitors (GMPs), confirming
that a gradual restriction in the differentiation potential
is associated with an upregulation of lineage-specific
genes and silencing of lineage-inappropriate genes.
In HSCs we detected high levels of H3K27me3 and
relatively low levels of H3K4me3 (Figure 3d); a pattern
consistent with the accepted criteria for a bivalent chro-
matin signature (and as defined for this gene in pluripo-
tent ES cells). The levels of H3K27me3 (and its
associated methyltransferase EZH2) in HSCs, CMPs,
GMPs, MEPs and EBV-Ly cells were similar and
decreased as MEPs differentiated into erythroid cells
(Figure 3d and see Additional file 4). By contrast the
levels of H3K4me3, associated with the parallel increase
of expression, started to increase as CMPs differentiated
into MEPs, prior to the clearance of PcG and
H3K27me3. Therefore, at each of these stages of differ-
entiation, the ratio of H3K4me3/H3K27me3 changed,
reflecting the level of a globin expression (Figure 3a).
Bivalent genes with a higher H3K4me3 occupancy at the
promoter are more often transcribed in ES cells
In genome-wide analyses it has been shown that, in gen-
eral, the level of H3K4me3 modification correlates with
gene expression and H3K27me3 correlates with
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silencing [16,17,31,32]. But does this correlation also
apply to bivalent genes? The detailed analysis of a single
gene presented here shows that, at the bivalent a globin
locus, changes in the levels of basal gene expression are
reflected by changes in the H3K4me3 mark. Is this
behaviour an exception? Here we evaluated the relation-
ship between H3K4me3/H3K27me3 modifications and
gene expression at other, previously identified bivalent
genes.
On a global scale, we determined how the H3K4me3/
H3K27me3 ratio differed at bivalent genes known to be
expressed at different levels in ES cells. Data from
human ES cell studies [4,6] were crossreferenced and
the bivalent genes subdivided into three ‘bins’ according
to their expression. We found that in a population of ES
cells, the chromatin associated with genes with the high-
est expression had the highest H3K4me3/H3K27me3
ratios, while those with the lowest relative expression
had the lowest ratios (Figure 4a). In addition, there was
a significant positive association between the absolute
level of RNA expression and the H3K4me3/H3K27me3
ratio at the associated transcription start sites (TSSs) (P
= 2.2 × 10-16) (Figure 4b). We also analysed the same
data set plotting for each individual bivalent gene the
ratio of H3K4me3/H3K27me3 against expression.
Clearly they follow the same trend but, due both to
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biological variation and insensitivity of microarray data
to low levels of transcription, there is a considerable
scatter (see Additional file 5).
In a cell population, the relative levels of H3K4me3/
H3K27me3 at previously identified bivalent genes could
reflect the relative proportions of cells in which the
gene in question is marked exclusively by H3K4me3 or
H3K27me3. To address this we looked at a subset of the
previously studied bivalent loci with the highest levels of
H3K27me3 (top 20%). It seemed likely that, for this set,
the genes in question would be modified by H3K27me3
in most, if not all, cells. So it was of interest that, even
in this subgroup, we found a significant positive associa-
tion between the absolute levels of RNA expression and
the levels of associated H3K4me3 (P = 2.25 × 10-8) (see
Additional file 6). Therefore, in comparison to other
more stringent forms of silencing (for example DNA
methylation), PcG silencing may be incomplete and
allow stochastic gene expression.
Finally, we examined the relationship between the
ratio of H3K4me3/H3K27me3 at specific bivalent
genes and the ability to detect single-cell transcripts
expressed from these genes. It has been reported that,
as for a globin, expression of other bivalent genes can
be sporadically detected in single ES cells [29]. The
bivalent genes studied by Gibson et al . [29] were
crossreferenced with ChIP data from Ku et al. [6] and
subdivided into three classes according to the propor-
tion of cells in which the transcript was detected.
Although the number of genes analysed by single-cell
RT-PCR was small, we found that there was a clear
tendency for the genes whose transcripts were never
detected, to have the lowest H3K4me3/H3K27me3
ratios (Figure 4c).
Conclusions
The central question raised here is whether or not biva-
lent domains, marked both by repressive (H3K27me3)
and active (H3K4me3) histone modifications, represent
a preprogrammed epigenetic signature of silent but
poised chromatin or more simply reflect different
degrees of silencing (H3K27me3) and transcription
(H3K4me3) within a population of cells. The observa-
tion that most clearly supports the prevailing concept of
a preprogrammed epigenetic mark in pluripotent cells is
the presence of bivalent domains in which, despite the
presence of both activating (H3K4me3) and repressive
(H3K27me3) marks, no PolII elongation and full length
transcription are detected, leading to the conclusion that
all of such genes are poised [8,9]. However through eva-
luation of public datasets it is readily notable that the
levels and patterns of histone modifications at bivalent
genes are very variable. Similarly, a wide range of
H3K4me3 levels within bivalent domains of embryonic
and haematopoietic stem and progenitor cells has been
recently identified [13,19].
Here, the detailed analysis of a single well charac-
terised bivalent gene (a globin) expressed during hae-
matopoiesis and the global analysis of the relationship
between H3K4me3/H3K27me3 ratio and gene expres-
sion suggest another explanation for bivalent chromatin
domains that might be considered. It is possible that
some genes with bivalent signatures may be poised in
pluripotent cells by a common but as yet undefined
molecular mechanism. If so, then it is not clear why the
associated chromatin modifications are so variable. An
alternative explanation, proposed here, is that bivalently
marked genes are regulated by PcG and marked by
H3K27me3; the different levels of associated H3K4me3
may simply be a sensitive marker of different levels of
transcriptional activity. The latter scenario is consistent
with previous observations showing that many lineage-
specific genes can be stochastically expressed at low but
variable levels in multipotent cells (so called multiline-
age priming) [33].
Although both situations could be considered to be
poised the underlying mechanisms and their implica-
tions are different. In fact, the first model (repressed but
poised for later activation) implies that most of the cells
harbour coexisting repressive and activating marks and
that both PcG and trxG have to be maintained at the
given locus through cell divisions to keep the repressed-
but-poised status until further changes in the balance of
their activity. By contrast, the second (repressed and
marked by variable degrees of stochastic transcription)
implies that PcG is not fully efficient at repressing sto-
chastic transcriptional noise. This would provide fertile
ground for subsequent activation and changes in cell
fate decisions as a tissue-specific transcription factor
programme emerges [34]. Definitive experiments to dis-
criminate between these two possibilities will require
the development of assays to correlate chromatin modi-
fication and gene expression within single cells.
Methods
Ethics
The part of the study involving human participants was
approved by the Institutional Ethics Committee
(approval number 06/Q1606/110). A written informed
consent was obtained from all patients.
Primary cells and cell culture
EBV-Ly cell lines were cultured in RPMI 1640 supplemen-
ted with 10% (v/v) fetal calf serum, 2 mM l-glutamine,
50 U/ml penicillin and 50 μg/ml streptomycin. Isolation
and culture of primary human erythroblasts was carried
out as described previously [35]. The human embryonic
stem cell line, H1 (WiCell, Madison, WI, USA), was
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grown on irradiated mouse embryonic fibroblasts in med-
ium containing Dulbecco’s modified Eagle medium
(DMEM):F12, serum replacer (Invitrogen, Paisley, UK), l-
glutamine, b-mercaptoethanol, non-essential amino acids
and basic fibroblast growth factor (8 ng/ml). Cells were
passaged every 5-7 days with collagenase IV to maintain
undifferentiated human embryonic stem cells.
Flow cytometric analysis and sorting
Normal human bone marrow samples were collected
from individuals undergoing total hip replacement for
osteoarthritis. CD34+ cells were enriched using MACS
(Miltenyi Biotech, Bergisch Gladbach, Germany) immu-
nomagnetic beads and cryopreserved in 90% fetal bovine
serum (FBS)/10% dimethylsulfoxide (DMSO). All experi-
ments were carried out using cryopreserved CD34+
cells that were thawed, washed in Iscove’s modified Dul-
becco’s medium (IMDM)/10% FBS and cultured over-
night in StemSpanSFEM (StemCell Technologies,
Grenoble, France) in the presence of recombinant
human stem cell factor (100 ng/ml), Flt3-ligand (100
ng/ml) and thrombopoietin (100 ng/ml) (Peprotech,
Rock Hill, NJ, USA).
CD34+ cells were first stained with purified anti-CD2,
RPA-2.10; CD3, HIT3a; CD4, RPA-T4; CD7,124-1D1;
CD8, RPA-T8; CD10, CB-CALLA; CD11b, ICRF44;
CD14, 61D3; CD19, HIB19; CD20, 2H7; CD56,
MEM188; GPA, GA-R2 (eBioscience, San Diego, CA,
USA). Subsequently cells were stained with Pacific Blue
conjugated goat F(ab’)2 anti-mouse IgG conjugates (H
+L) (Invitrogen). Finally, cells were stained with fluores-
cein isothiocyanate (FITC)-conjugated anti-CD38
(HIT2), phycoerythrin (PE)-conjugated anti-CD45RA
(HI100), PE-Cy7-conjugated anti-CD123 (6H6)
(eBioscience), PE-Cy5-conjugated anti-CD34 (581)
(Beckman Coulter, High Wycombe, UK) and allophyco-
cyanin (APC)-conjugated anti-CD110 (BAH-1) (Becton
Dickinson, Franklin Lakes, NJ, USA). HSCs were iso-
lated as Lin- CD34+ CD38-, CMPs as Lin- CD34+
CD38+ CD123low/+ CD45RA- CD110-, GMPs as Lin-
CD34+ CD38+ CD123+ CD45RA+ CD110- and MEPs
as Lin- CD34+ CD38+ CD123-/low CD45RA- CD110-.
Dead cells were excluded by Hoechst 33258 (Invitrogen)
staining or by 7-aminoactinomycin D (Sigma-Aldrich,
Gillingham, UK). Appropriate unstained, single stained
and Fluorescence Minus One controls were used to
determine the background staining level and compensa-
tion in each channel. All sorting and analyses were per-
formed on three laser-equipped MoFlo (Dako
Cytomation, Ely, UK) or BD FACS AriaII (Becton Dick-
inson) machines. Single ES cells were sorted with an
automated cell deposition unit into 96-well plates. FACS
data were analysed with Summit software (Dako
Cytomation).
ChIP assays
ChIP analyses were performed according to the Milli-
pore ChIP protocol (Millipore 17-295, Billerica, MA,
USA), as described previously [26]. Input and immuno-
precipitated material were analysed by real time PCR
using a series of PCR amplicons and 5’FAM-3’TAMRA
probes across the a globin locus [26]. ChIP-chip experi-
ments were carried out on the custom a globin tiling
path microarray, as described previously [22]. The
enrichment of ChIP DNA over input DNA was calcu-
lated as ratio of the background corrected ChIP signal
divided by the background corrected input signal (both
globally normalised). The antibodies used in the experi-
ments were: anti-mono/di/trimethyl Lys4 histone H3
(07-436, 07-030, and 07-473, respectively), anti-trimethyl
Lys27 histone H3 (07-449) and anti-trimethyl Lys9 his-
tone H3 (07-442 lot 24416) from Millipore; anti-tri-
methyl Lys36 histone H3 (ab9050) from Abcam
(Cambridge, UK); anti-RNA-PolII (H224) from Santa
Cruz Biotechnology (Santa Cruz, CA, USA), anti-EZH2
(36-6300) from Zymed (San Francisco, CA, USA).
For ChIP in the artificially mixed population of cells,
10% of primary erythroblasts were mixed with 90% of
EBV-ly cells. At any one time, about 80% of erythroid
cells are positive for nascent a globin RNA transcripts
[36] and 100% of these cells accumulate high levels of
globin RNA during the late stages of erythropoiesis.
Therefore these cells are presumed to be 100% modified
by H3K4me3. By contrast, in lymphocytes, the a globin
genes are repressed and the H3K4me3 signal at the a
globin promoter is at background level.
Sequential ChIP analyses were performed as follows: 5
μg of H3K4me3 or H3K27me3 antibody were immobi-
lised to 50 μl of protein A agarose beads (Millipore) by
crosslinking with 2.5 mM BS3 (Thermo Fisher Scientific,
Waltham, MA, USA). Chromatin precipitated using the
first antibody was eluted in 500 μl of 0.1 M NaHCO3
and 1% SDS. This solution was then diluted tenfold in
ChIP Dilution buffer (Millipore) and subjected to immu-
noprecipitation using the second antibody. The second
antibody was not crosslinked to protein A.
Gene expression analysis
Total RNA was extracted using TriReagent (Sigma).
Contaminating DNA was removed from RNA preps
with the DNA-free kit (Ambion/Applied Biosystems,
Austin, TX, USA) according to the manufacturer’s
instructions. cDNA was generated using 1-5 μg of total
RNA and random primers using the Prostar RT-PCR kit
(Stratagene/Agilent Technologies, Santa Clara, CA,
USA). Negative control cDNA samples generated with-
out reverse transcriptase were analysed in all experi-
ments. Real time qPCR experiments were carried out on
ABI Prism 7000 Sequence Detection System (Applied
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Biosystems) using a set of primers/probe detecting
HBA2 cDNAs (see Additional file 7). The results were
normalised to a control sequence in the 18S ribosomal
RNA (RNRI) gene (Eurogentec, Southampton, UK). To
detect short abortive transcripts at the 5’ region of HBA
cDNA, two different sets of primers were used in a
SybrGreen qPCR reaction (see Additional file 7).
Multiplex single-cell RT-PCR analysis was performed
as previously described [33,37]. Single cells were depos-
ited into 96-well PCR plates using a single cell depositor
unit coupled to a fluorescence-activated cell sorting
(FACS) ARIAII cell sorter (providing single cells in
>99% of the wells, and no wells with more than 1 cell as
assessed by routinely sorting fluorescent beads or cells
prior to and after single cell sorting). Each well con-
tained 4 μl of lysis buffer (0.4% NP40, 2.3 mM dithio-
threitol (DTT), 0.07 mM dNTP, 0.5 U/μl Rnase
Inhibitor). Cell lysates were reverse transcribed in a 10
μl reaction with Superscript III Reverse Transcriptase
(Invitrogen) and gene-specific primers (R1s in Addi-
tional file 7). A first round of PCR (40 cycles) was per-
formed by the addition of a PCR mix containing PCR
buffer, 1.25 U of Taq polymerase (Invitrogen) and gene-
specific forward primers (F1s in Additional file 7). A
total of 1 μl of 1:10 diluted first-round PCR products
were amplified in a second-round PCR, which was car-
ried out using fully nested gene-specific primers (F2-R2
in Additional file 7). PCR products were gel electrophor-
esed and visualised by ethidium bromide staining. Only
control-positive (OCT4 in ES cells, HPRT in EBV-Ly)
wells were considered as informative and scored. A total
of 270 individual human ES cells and 110 EBV-Ly were
analysed.
Statistical analysis
In order to correlate genes expression and chromatin
state in human ES cells, expression data (accession
number GSE8439 [4]) and single cell transcript detec-
tion data [29] were crossreferenced with ChIP-Seq
data (accession number GSE13084 [6]). The promoter
chromatin state was calculated as relative ratio of the
signal derived from the number of H3K4me3 and
H3K27me3 sequence reads across a window between
-3 kb and +3 kb of the annotated TSS. The relation-
ship between H3K4me3/H3K27me3 ratio and expres-
sion was calculated by averaging of the H3K4me3/
H3K27me3 ratio within a sliding window 100 observa-
tions wide, incrementing by 1, using a Spearman rank
correlation. Considering the different source of the
two ES cell datasets (H1, male cell line, for expression
data and H9, female cell line, for ChIP-Seq data), X-
chromosome linked genes were excluded from the
analysis.
Additional material
Additional file 1: Example of contiguous bivalent domains differing
in the extent of H3K4me3 and H3K27me3. The level and distribution
of H3K4me3 and H3K27me3 at two contiguous bivalent domains (CDX2
and FLT3) are shown in comparison to a housekeeping gene (PAN3),
which is only modified by H3K4me3. The profile of the two modifications
are from Ku et al [6].
Additional file 2: Expression of fully-spliced and 5’-transcript a
globin in embryonic stem (ES) cells and differentiated cells.
Expression level of a globin and HBM transcripts is shown relative to
18S. The error bars represent the standard deviation of three
independent experiments. EBV-Ly = Epstein-Barr virus (EBV)-transformed
lymphoblastoid cell line; Ery = primary erythroblasts; ES = ES cells. HBA 5’
Primer Set 1 and HBA 5’ Primer Set 2, both spanning the 5’ untranslated
region (UTR) and the first exon of a globin, were used in order to detect
5’ abortive transcripts.
Additional file 3: H3K36me3 and H3K9me3 marks at the telomeric
region of chromosome 16p. Both of these chromatin marks have been
associated with actively transcribed regions [3,38]. The genomic region is
annotated as in Figure 1. The y axis represent the enrichment of
chromatin immunoprecipitation (ChIP) DNA over input DNA calculated
as ratio of the background corrected ChIP signal divided by the
background corrected input signal (both globally normalised). The red
shaded box represents the a cluster locus. EBV-Ly = Epstein-Barr virus
(EBV)-transformed lymphoblastoid cell line; Ery = primary erythroblasts; ES
= embryonic stem (ES) cells.
Additional file 4: EZH2 chromatin immunoprecipitation quantitative
PCR (ChIP-qPCR) in pluripotent cells, hematopoietic progenitors
and differentiated cells. Real-time qPCR analysis of EZH2 ChIP
performed in embryonic stem (ES) cells (ES), hematopoietic stem cells
(HSCs), common myeloid progenitors (CMPs), granulocyte-monocyte
progenitors (GMPs), megakaryocyte-erythroid progenitors (MEPs), primary
erythroblasts (Ery), and Epstein-Barr virus (EBV)-transformed
lymphoblastoid cell line (EBV-Ly). C16orf8 promoter is a positive control
promoter in which the silencing effect of PcG and H3K27me3 occurs late
in differentiation [27]. MCS-R3 is a PcG/H3K27me3 negative amplicon.
The error bars show the standard deviation of two independent
experiments
Additional file 5: Correlation between expression level and
H3K4me3/H3K27me3 occupancy. The increasing trend in H3K4me3/
H3K27me3 ratio (y axis, log2 scale) with respect to expression (x axis, log
10 scale) is shown as an XY scatterplot. Each circle corresponds to a
single bivalent gene. A line corresponding to the median expression
level (2.43) of all genes expressed in embryonic stem (ES) cells, as from
Pan et al. [4], is shown. Lines corresponding to 25th, 50th and 75th
percentiles of the H3K4me3/H3K27me3 ratio are also shown. Bivalent
genes analysed in sequential chromatin immunoprecipitation (ChIP) in
the current study are displayed in colour and labelled. a Globin and
HBM are shown as red and purple dots, respectively. The 20-period
moving average trendline is displayed.
Additional file 6: Correlation between expression level and
H3K4me3/H3K27me3 occupancy in the top 369 H3K27me3
modified bivalent genes in embryonic stem (ES) cells. The increasing
trend in H3K4me3/H3K27me3 ratio [6] with respect to expression [4] is
shown by averaging within a sliding window 20 observations wide,
incrementing by 1. Spearman’s r value is shown in the graph.
Additional file 7: Primers. Primers used in expression analysis.
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